We also evaluated the safety profiles of different anti-cancer treatment regimens through the reporting of serious adverse events (SAEs), specific adverse events relevant to HER2-targeted therapies (including cardiac toxicity) and AEs leading to treatment discontinuation or dose modification of an anti-cancer therapy. This evidence concerns the gene ERBB2 and cancer.